The 2025 targets include achieving around €62 billion in revenues, falling costs in absolute terms, a stable cost of risk, ...

Q1 2025 Earnings Conference Call April 3, 2025 9:00 AM ETCompany ParticipantsAlex Ng - VP-Corporate Development ...

Aker Horizons ASA (the "Company") hereby publishes its Annual Report 2024, which comprises the Board of Directors' Report including the Sustainability Statement, the consolidated accounts, parent ...

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today ...